Skip to content
by Legal Desire
8 November 2025

Latham & Watkins Advises 4D Molecular Therapeutics on US$100 Million Offering of Common Stock and Pre-Funded Warrants

Advising firms

Deal team

17 lawyers named
LawyerFirmSeniorityPracticeOffice
Mark Roeder Lead Latham & Watkins LLP Partner corporate Bay Area
John Williams Lead Latham & Watkins LLP Partner corporate Bay Area
Raul Gonzalez-Casarrubias Latham & Watkins LLP Associate corporate Not stated
Lexi Zintel Latham & Watkins LLP Associate corporate Not stated
Keran Huang Latham & Watkins LLP Associate corporate Not stated
Elizabeth Richards Latham & Watkins LLP Partner regulatory Washington, D.C.
Betty Pang Latham & Watkins LLP Partner regulatory Bay Area
Chad Jennings Latham & Watkins LLP Counsel regulatory Washington, D.C.
Evan Miller Latham & Watkins LLP Associate regulatory Not stated
Heather Deixler Latham & Watkins LLP Partner data privacy and cybersecurity Bay Area
Sarah Zahedi Latham & Watkins LLP Associate data privacy and cybersecurity Not stated
Grace Lee Latham & Watkins LLP Partner tax Bay Area
Dennis Poehland Latham & Watkins LLP Associate tax Not stated
Maj Vaseghi Latham & Watkins LLP Partner benefits and compensation Bay Area
Christopher Hazuka Latham & Watkins LLP Partner intellectual property San Diego/Bay Area
Robert Yeh Latham & Watkins LLP Counsel intellectual property San Diego
Kristina Funahashi Latham & Watkins LLP Associate intellectual property Not stated

Stated terms

Stated value
USD 100m (US$100 million)
What the figure measures
Issue size
Client
4D Molecular TherapeuticsIssuer
Counterparties
Not stated